|1.||Januzzi, James L: 69 articles (12/2015 - 08/2004)|
|2.||Mueller, Christian: 57 articles (03/2015 - 12/2002)|
|3.||Burnett, John C: 50 articles (07/2015 - 02/2002)|
|4.||Maisel, Alan S: 49 articles (12/2015 - 02/2002)|
|5.||Omland, Torbjørn: 40 articles (10/2015 - 02/2002)|
|6.||Maisel, Alan: 39 articles (05/2015 - 01/2002)|
|7.||Clopton, Paul: 37 articles (12/2015 - 01/2002)|
|8.||O'Connor, Christopher M: 37 articles (12/2015 - 01/2002)|
|9.||Richards, A Mark: 36 articles (12/2015 - 05/2002)|
|10.||Wu, Alan H B: 34 articles (03/2012 - 07/2002)|
02/01/2003 - "The results of several recent clinical trials have shown that administration of nesiritide is safe and highly effective for the initial treatment of patients with acutely decompensated heart failure and can help physicians and nurses meet treatment goals for the management of patients with this serious condition."
11/01/2004 - "Nesiritide has proven to be an effective new treatment for patients with decompensated heart failure."
03/01/2004 - "Nesiritide is a newer neurohormonal agent with proven efficacy and safety for use in decompensated heart failure, but appropriate patient selection has been challenging for clinicians. "
03/01/2015 - "There was significant improvement in NYHA class (3.0 vs 2.1, P = .002; 13/17 improved); Minnesota Living with Heart Failure Questionnaire (42 ± 26 vs 27 ± 22, P = .026; 12/17 improved); peak maximum oxygen consumption (14.6 ± 3.3 vs 16.5 ± 3.9 mL/kg/min, P = .013; 10/15 improved); LVEF (25% ± 6% vs 37% ± 8%, P<.001; 14/16 improved); and LV end-systolic volume (174 ± 57 vs 137 ± 37 mL, P = .002; 11/16 improved) but not in N-terminal prohormone brain natriuretic peptide. "
01/01/2013 - "Although no significant correlation was observed between plasma brain natriuretic peptide (BNP) and plasma miR-210 levels in patients with NYHA II heart failure, patients with an improved BNP profile at the subsequent hospital visit were classified in a subgroup of patients with low plasma miR-210 levels. "
|2.||Dyspnea (Shortness of Breath)
12/01/2011 - "Most recently, findings from the ASCEND-HF trial showed that nesiritide was safe with no adverse effects on renal function or mortality and was associated with a modest improvement in dyspnea. "
04/17/2012 - "Nesiritide had a greater effect than placebo on PEFR, and this predicted patients with moderate/marked improvement in dyspnea, thereby providing an objective metric for assessing AHF. "
02/01/2009 - "Prior studies have shown that dyspnea is improved in patients with ADHF 3 hours after nesiritide infusion with significant dose-related reductions in cardiac filling pressures and systemic vascular resistance without significant arrhythmias. "
02/12/2004 - "Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide in the emergency department improved the evaluation and treatment of patients with acute dyspnea and thereby reduced the time to discharge and the total cost of treatment."
07/07/2011 - "Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. "
|3.||Body Weight (Weight, Body)
08/01/2015 - "LVH was assessed from heart-weight/body weight ratio, histology and brain natriuretic peptide expression. "
05/01/2015 - "Decreased voluntary running distances, increased lung/body weight ratios, and increased brain natriuretic peptide levels in cMyBP-C(t3SA) mice demonstrate that phosphorylation deficiency is associated with signs of HF. "
01/01/2015 - "We observed that left ventricular wall thickness in end diastole, heart size, heart weight-to-body weight ratio, heart weight-to-tibia length ratio, cross-sectional area of cardiomyocytes and the reactivation of fetal genes (atrial natriuretic peptide and brain natriuretic peptide) were markedly increased, meanwhile left ventricular internal dimension at end-diastole, systolic function were significantly decreased by TAC at 4 wks after operation (P < 0.01), all of which were effectively inhibited by EP treatment (P < 0.05), but the differences of these parameters were decreased at 8 wks after operation. "
12/01/2013 - "Basal plasma concentrations of N-terminal pro-B-type natriuretic peptide in clinically healthy adult small size dogs: effect of body weight, age, gender and breed, and reference intervals."
01/01/2013 - "Body weight, plasma B-type natriuretic peptide concentration, and HF symptom score decreased significantly in "responders", but remained unchanged in "non-responders". "
01/01/2010 - "Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial."
01/01/2014 - "The intra-aortic balloon pump improved the hemodynamic index and cardiac function and decreased brain natriuretic peptide concentration in patients with acute anterior wall ST-elevation myocardial infarction. "
08/01/2013 - "Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction."
07/01/2007 - "In ST-elevation myocardial infarction (STEMI) B-type natriuretic peptide (BNP) holds promise for risk stratification. "
04/15/2006 - "We investigated whether N-terminal pro-brain natriuretic peptide (NT-pro-BNP) that was measured on admission in patients with acute myocardial infarction (AMI) predicts the efficacy of reperfusion or whether NT-pro-BNP provides prognostic information independent of infarct size as estimated by single-photon emission computed tomographic scintigraphy. "
|5.||Heart Diseases (Heart Disease)
05/01/2013 - "The patients with univentricular heart disease with an adverse outcome had a significantly greater 24-hour B-type natriuretic peptide level than those without (P < .05). "
09/01/2011 - "To determine plasma B-type natriuretic peptide (BNP) levels in children with heart diseases before medical or surgical treatment for monitoring therapeutic efficacy in an observational prospective clinical trial at tertiary care centre. "
07/01/2013 - "Efficacy of N-terminal pro-brain natriuretic peptide digit number for screening of cardiac disease in new haemodialysis patients."
07/01/2009 - "We wanted to evaluate if brain natriuretic peptide (BNP) is cleared during continuous veno-venous hemofiltration (CVVH) sessions in children with congenital heart disease. "
06/01/2015 - "The aim of the study was to evaluate the exercise capacity of children and adolescents with cyanotic congenital heart disease and to assess respiratory muscle strength, plasma levels of B-type natriuretic peptide and ventricular ejection fraction, as well the associations between these variables. "
|1.||pro-brain natriuretic peptide (1-76)
|2.||Brain Natriuretic Peptide (Natrecor)
|3.||Biological Markers (Surrogate Marker)
|4.||Messenger RNA (mRNA)
|5.||Atrial Natriuretic Factor (ANF)
|1.||Cardiac Resynchronization Therapy
|3.||Renal Dialysis (Hemodialysis)
|4.||Intensive Care (Surgical Intensive Care)